The combination of first-line nivolumab and ipilimumab demonstrated an improvement in overall survival compared to platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma. The study showed a two-year overall survival rate of 40.8% for the treatment arm vs 27.0% for the chemotherapy arm.
The addition of sintilimab to pemetrexed and platinum chemotherapy significantly improved progression-free survival in patients with non-squamous non-small cell lung cancer, with a nearly two-fold increase observed. The overall response rate was also higher in the sintilimab-combination group compared to the placebo combination.
In a Phase 3 study, ensartinib demonstrated statistically significant longer progression-free survival compared to crizotinib in ALK+ NSCLC patients. The study found that ensartinib significantly prolonged overall response rate and time-to-treatment-failure rate in brain metastases